Cash
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive155AccountSocial
MARKETSINVESTLIVE155
Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
Series Image
  1. Biotech

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)




Order book
Order book


FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

Odds
82% chance
Max payout
Mar 31, 2027
$0
$0 vol
More Financials Markets

Trending Financials markets

When will Jensen Huang leave as Nvidia CEO?S&P price today at 4pm EST?Nasdaq-100 price today at 4pm EST?Nasdaq-100 close price end of 2026?S&P close price end of 2026?Coca-Cola Point of Sale Growth in November 2026Pepsi Point of Sale Growth in November 2026Nicotine product point of sale spend array index in November 2026

Financials hub

All Financials markets